The optimization of aminooxadiazoles as orally active inhibitors of Cdc7.
2013
Abstract A series of aminooxadiazoles was optimized for inhibition of Cdc7. Early lead
isoquinoline1 suffered from modest
cell potency(cellular IC 50 = 0.71 μM measuring pMCM2), low selectivity against structurally related kinases, and high IV clearance in rats (CL = 18 L/h/kg). Extensive optimization resulted in azaindole 26 (Cdc7 IC 50 = 1.1 nM, pMCM2 IC 50 = 32 nM) that demonstrated robust lowering of pMCM2 in a mouse
pharmacodynamic(PD) model when dosed orally. Modifications to improve the pharmacokinetic profile of this series were guided by trapping experiments with glutathione in rat hepatocytes.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
-
Machine Reading By IdeaReader
23
References
16
Citations
NaN
KQI